Omexxel INC., Biosciences Division (PIBD) is a genomics and clinical data driven diagnostics, including companion diagnostics and cancer drugs development company founded in 2015. PIB is the Biotech division in diagnostics of Omexxel, and companion diagnostics and Next Generation Sequencing, NGS in USA – Southeast Asia, and one of the highest throughput sequencing labs in USA – Southeast Asia.

We possess state-of-the-art Polymerase Chain Reaction (PCR), which combined both Real-Time PCR technology using Fluorescent Probe and End-Point PCR using Dye-reporter Probe, and Next-Generation Sequencing (NGS) facility, which houses cutting-edge genome sequencing platforms such as Thermo Fisher’s QuantStudio 5, Agilent’s Aria Mx qPCR (formerly Stratagene’s Real-Time PCR, model Mx3005P), Illumina’s NovaSeq, HiSeq X , HiSeq 4000 and 2500, NextSeg, MiSeq Dx Instrument, and Thermo Fisher’s Ion PGM Dx System, Ion Torrent Genexus System, etc. and Our Sequencing facility is supported by a sophisticated IHC pathology lab and we even utilize modern molecular techniques such as FISH, PCR, Sanger Sequencing, and Microarray to offer comprehensive diagnostic solutions to researchers, doctors, and hospitals.

Our footprint covers the whole of Vietnam and parts of Southeast Asia with over 500 hospitals and more than 5,000 clinicians leveraging our services. PIB has successfully partnered with major hospitals and research centers across Vietnam. We have setup Genomic Centers in key cities across Vietnam to create awareness about the utility and efficacy of genetic testing in a clinic and offer services that are relevant and affordable to patients to manage their health outcomes.

Innovation is our core belief and many of our tests have been developed in-house including our Comprehensive Gene Panels. Our liquid biopsy test OncoTrack for monitoring cancer treatment is the only PCR and NGS-based ctDNA test available in Vietnam. We even offer carrier screening test for couples planning a baby and whole exome sequencing test for identifying gene mutations in rare diseases. We believe in continuous innovation to help reduce the cost of genetic tests and empower clinicians with actionable clinical insights to provide better outcomes.

As a firm believer in quality, PIB adheres to the highest international standards when it comes to services and has obtained the prestigious CAP accreditation for labs across Vietnam. Our business has grown two-fold in the past 3 years and now we also offer diagnostics services in Southeast Asia, Middle East, Eastern Europe, and Africa. Our expert scientific team, data scientists, and bioinformaticians fuel our genomics research. We have successfully built research pipelines addressing immuno-oncology, biomarker discovery, companion diagnostics, and population-based genomic studies that taps the rich Vietnam diverse genotype.

We have worked extensively on building clinical databases of more than 1 million patients through collaborations. We have a repository of clinical, phenotypic, and genomics data for 100,000 patients to provide insights into complex diseases at genetic and molecular level. Since the company works extensively in the Vietnam sub-continent, we have access to data that provides insights into genetic diversity of Vietnam population for more than 500 population groups. Over the years we have also focused on building tools and IP that could be leveraged by researchers and pharmaceutical companies to aid in drug discovery and clinical trial. These tools cover disease segments such as oncology, diabetes, ophthalmology, cardiology, and other rare diseases. PIB is a founding member of Genome Asia 100K, an initiative to sequence 100,000 Genomes in Asia, which would enable us to provide a unique resource of genetic research for the world.

Headquartered in California, USA we have a workforce of more than 450 people across the globe with offices in Vietnam, Cambodia, Laos, Burma Myangma, Indonesia, Philippines, India.